TrialRMD open2022

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.

Jeffrey I Weitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.